

INTENDED USE: THIS PRODUCT IS FOR RESEARCH USE ONLY AND THEREFORE NOT INTENDED FOR CLINICAL OR DIAGNOSTIC USE.



The LPA Assay Kit II was co-developed using a proprietary monoclonal antibody from Lpath, Inc. (San Diego, CA). Lpath, Inc. has a number of patent applications pending or issued covering material(s) incorporated into this assay. **The assay's sole permitted use is for non-clinical research to measure LPA in biological samples.** Any other use, including drug discovery, requires a license from Lpath, Inc (www.lpath.com).



Lysophosphatidic Acid (LPA) Assay Kit II Technical Data Sheet

Product Number: K-2800S

96 tests

Materials Provided

Catalog #	Description	Amount
K-2801S	Biotinylated Anti-LPA Antibody	< 100 µL
K-2805L	Lysophosphatidic Acid (LPA C18:3) Standard	238 µg
K-2807S	LPA Detection Plate	1 Plate
K-SEC3h	Streptavidin HRP	80 µL
K-PBST4	Sample Diluent	10 mL
K-PBST2	10X PBS-T Buffer	20 mL
K-TMB1	TMB Substrate	12 mL
K-STOPt	1N Sulfuric Acid (H ₂ SO ₄)	10 mL
---	Microtiter plate seal	2 Seals

Additional Materials Provided by User

- Pipettes (capable of delivering between 5 and 1,000 µL with appropriate tips)
- Multichannel pipettes
- Absorbance microplate reader capable of reading at 450 nm

Storage

Upon receipt, store the kit box (Part 1) at 4 °C and store the LPA standard (K-2805L) at -80 °C. The LPA standard is not stable at temperatures < -70 °C. Under proper storage conditions, this product is stable for at least 6 months from date of receipt. Opened and reconstituted solutions are less stable. All components and solutions should be protected from excessive light and heat.

Introduction

Lysophosphatidic Acid Background

Lysophosphatidic Acid (LPA) is a serum-derived phospholipid involved in diverse cellular processes such as cell proliferation, chemotaxis, platelet aggregation, wound healing, angiogenesis, tumor invasion, and smooth muscle contraction. Recent research indicates LPA may play a significant role in the pathophysiology of cancer and may be used as a biomarker for ovarian cancer.

Assay Design

The Lysophosphatidic Acid (LPA) Assay Kit II is an enzyme-linked immunoassay designed for the *in vitro* measurement of LPA in biological samples. The assay is a competitive ELISA in which the colorimetric signal is inversely proportional to the amount of LPA present in the sample; as a sample has greater amounts of LPA the colorimetric signal is reduced. Briefly, the samples are pre-mixed with LPath's biotinylated anti-LPA antibody and a sample diluent before the mixtures are added to the LPA coated detection plate for competitive binding. Streptavidin-HRP and colorimetric detection are used to detect the amount of biotinylated anti-LPA bound to the plate. The concentration of LPA in the sample is determined using a standard curve of known amounts of LPA. This assay is read at 450 nm and requires 2 hours to run.

Assay Range: 0.064 μ M to 1,000 μ M

Sensitivity:

The limit of detection (LOD), defined as the lowest amount of LPA in a sample detectable from zero, was calculated at 0.12 μ M. The limit of quantification (LOQ) or the lowest concentration detected within the linear range of the curve was calculated at 0.024 μ M. The LOD and LOQ values are from an average of 4 experiments.

Specificity:

No significant cross reactivity was observed against any lipid tested. The lipids we selected for testing were related in structure and signaling pathway. For a complete list of the lipids tested please contact customer service. As it is impossible for us to run a complete cross-reactivity and interference test on the assay, cross reaction may still exist.

Assay Precision:

The assay's precision was determined with 4 human serum samples and 2 human plasma samples. The experiments were run in triplicate, 4 times, with two lots of kits.

Intra-assay (precision within an assay): 6.5-8.7%

Inter-assay (precision between assays): 8.9-15.33%

Sample Type: This kit can detect LPA from human or animal in serum, plasma and tissue homogenate.

Sample Volume: For duplicate data points 20 μ L of each sample is required.

Precautions

Assay Performance

For best results, please follow the protocols provided. Not following the instructions may result in suboptimal performance of the kit and failure to produce accurate data.

Research Use Only

Echelon Biosciences products are sold for research and development purposes only and are not for diagnostic use or to be incorporated into products for resale without written permission from Echelon Biosciences. Materials in this publication, as well as applications and methods and use, may be covered by one or more U.S. or foreign patents or patents pending. We welcome inquiries about licensing the use of our trademarks and technologies at busdev@echelon-inc.com


LPA Assay Kit II Notes

1. Ensure samples are free from debris before adding to the plate.
2. Ensure all reagents are warmed to room temperature before use. Failing to do so might result in edge effects and increased CV's.
3. Samples/standards: Antibody: Sample Diluent mixing ratio, in step 5) is 1:9:10. Volumes can be adjusted. Ensure Sample Diluent is added last and mixture is mixed by vortexing for 1-2 seconds to achieve the optimal assay reproducibility.
4. **When analyzing biologic samples we advise running a known normal (low) LPA sample and a disease (high) LPA sample in conjunction with your unknown samples. These will serve as positive and negative controls to distinguish between normal healthy samples and disease samples.**
5. The antibody used in this assay has varied binding affinity to different LPA species. The order of the antibody affinity to different LPA species are C18:3 > C18:2 > Mixed LPA > C20:4 > C14:0 > C18:1 > C16:0 > C18:0. Mixed LPA contains LPA C16:0, C18:0, C18:1, C18:2 and C20:4 at 2.8:1:1.5:2.6:3 concentration ratios.
6. This assay is optimized for human serum and plasma LPA detection. The assay can be used for LPA detection in animal sample but it has not been optimized for non-human samples. Sample dilution may need to be optimized and is highly recommended before running a panel of samples.
7. The LPA Assay Kit II has been optimized for the detection of LPA in serum and plasma samples. Sample optimization is highly recommended for tissue homogenate samples.

Protocol for the detection of LPA

Please read this entire section and the assay notes section before beginning the assay.

Protocol Summary



Detailed Protocol for the detection of LPA in Serum or Plasma

This protocol has been developed for duplicate reaction points. If singlet or triplicate points are required, the protocol will need to be adjusted accordingly. To begin, prepare samples (see support protocols) and place the Streptavidin HRP (K-SEC3h), Biotinylated Anti-LPA Antibody (K-2801S), and LPA Standard (K2805L) on ice. Allow the remaining kit components to warm to room temperature before use.

1. Prepare 1X PBST by diluting the bottle of 10X PBS-T Buffer (K-PBST2) with 180 mL deionized water. Store prepared 1X PBST at room temperature.
2. Reconstitute the LPA Standard (K-2805L)
 - a. For serum or plasma samples, reconstitute the LPA Standard (K-2805L) with 50 μ L of 1X PBST (step 1) for 1,000 μ M solution. Vortex to mix and keep at room temperature. The reconstituted LPA standard can handle at least one freeze-defrost cycle and 6 months storage < -20°C.
 - b. For tissue homogenate samples, reconstitute the LPA Standard (K-2805L) with 50 μ L of tissue homogenate buffer (see buffer recipe in support protocols) for 1,000 μ M solution. Vortex to mix. Keep at room temperature. If samples have been prepared in two different buffers then a separate standard curve will need to be made for each sample buffer used. An extra LPA standard can be purchased under cat# K-2805L. The standards stability in homogenate buffer is unknown.
3. Vortex the reconstituted LPA standard (step 2) and prepare the 7 LPA standard dilutions in 1X PBST (step 1) or homogenate buffer using the table below.

LPA Concentration	Amount of 1,000 μ M LPA Stock (Step 3) or Previous Dilution	Amount of 1X PBST or homogenate buffer
1000 μ M	45 μ L of 1000 μ M LPA Solution	None
200 μ M	5 μ L of 1000 μ M LPA Solution	20 μ L
40 μ M	5 μ L of 200 μ M LPA Solution	20 μ L
8 μ M	5 μ L of 40 μ M LPA Solution	20 μ L
1.6 μ M	5 μ L of 8 μ M LPA Solution	20 μ L
0.32 μ M	5 μ L of 1.6 μ M LPA Solution	20 μ L
0.064 μ M	5 μ L of 0.32 μ M LPA Solution	20 μ L
0 μ M (Pos. Ctrl)	0 μ L	25 μ L

4. Add 7 mL 1X PBST (step 1) directly into the Biotinylated Anti-LPA Antibody bottle (K-2801S). Mix well. Place at room temperature and immediately proceed to the next step. **This reagent is not stable at the working concentration and should be prepared immediately before use.** The diluted antibody can handle at least one freeze-defrost cycle and at

least a week's storage at -20 °C. A change in the assays signal may be observed. This reagent is not sold separately from the kit.

5. Combine the LPA standard (step 3), or samples, with the diluted antibody (step 4) and Sample Diluent (K-PBST4) in 1.5 mL polypropylene tubes in the following order. A 96-well incubation plate can be used instead of the 1.5 mL polypropylene tubes.
 - a. First, add 135 µL of the diluted antibody (step 4) into each tube. For negative control, add 135 µL of 1X PBST (step 1).
 - b. Second, add 15 µL of the LPA standards (step 3) or prepared samples into appropriate tubes. For positive and negative controls, add 15 µL of the solution used to dilute the standards. This should be 1X PBST (step 1) and/or homogenate buffer.
 - c. Third, add 150 µL of Sample Diluent (K-PBST4) to all tubes.
 - i. Ensure pipette tip does not contact the sample/antibody mixture to avoid cross contamination between samples.
 - ii. If precipitation is present in bottle of Sample Diluent (K-PBST4). Vortex vigorously until precipitate is dissolved.
 - d. Vortex each tube for 1-2 seconds to mix.
6. Remove the LPA Detection Plate (K-2807S) from plastic bag. Transfer 100 µL of the standards, controls and sample mixtures from the tubes in duplicate to the LPA Detection Plate (K-2807S) according to the "Suggested LPA Detection Plate Layout". For best results, prime the pipette 3-6 times before transferring. Cover the plate with a plate seal and incubate at room temperature for 1 hour.
7. After incubation, discard solutions from the LPA Detection Plate and wash with 200 µL/well of the 1X PBST (step 1) three times. Ensure all wash buffer is removed before proceeding to the next step.
8. Dilute 60 µL of the Streptavidin HRP (K-SEC3h) with 12 mL of the 1X PBST (step 1). Mix well. If you are running experiments over multiple days, only prepare what is needed for the day. **Prepare immediately before use.** The stock Streptavidin HRP (K-SEC3h) can withstand 3 freeze-defrost cycles and should be stored at -20°C between uses.
9. Add 100 µL/well of the diluted Streptavidin HRP solution (step 8) into each well of the LPA Detection Plate. Cover with new plate seal and incubate at room temperature for 1 hour.


Suggested LPA Detection Plate Layout

	1	2	3	4	5	6	7	8	9	10	11	12
A	1000 µM LPA	1000 µM LPA	Sample #1	Sample #1	Sample #8	Sample #8	Sample #16	Sample #16	Sample #24	Sample #24	Sample #32	Sample #32
B	200 µM LPA	200 µM LPA	Sample #2	Sample #2	Sample #9	Sample #9	Sample #17	Sample #17	Sample #25	Sample #25	Sample #33	Sample #33
C	40 µM LPA	40 µM LPA	Sample #3	Sample #3	Sample #10	Sample #10	Sample #18	Sample #18	Sample #26	Sample #26	Sample #34	Sample #34
D	8 µM LPA	8 µM LPA	Sample #4	Sample #4	Sample #11	Sample #11	Sample #19	Sample #19	Sample #27	Sample #27	Sample #35	Sample #35
E	1.6 µM LPA	1.6 µM LPA	Sample #5	Sample #5	Sample #12	Sample #12	Sample #20	Sample #20	Sample #28	Sample #28	Sample #36	Sample #36
F	0.32 µM LPA	0.32 µM LPA	Sample #6	Sample #6	Sample #13	Sample #13	Sample #21	Sample #21	Sample #29	Sample #29	Sample #37	Sample #37
G	0.064 µM LPA	0.064 µM LPA	Sample #7	Sample #7	Sample #14	Sample #14	Sample #22	Sample #22	Sample #30	Sample #30	Sample #38	Sample #38
H	Pos. Ctrl.	Pos. Ctrl.	Neg. Ctrl.	Neg. Ctrl.	Sample #15	Sample #15	Sample #23	Sample #23	Sample #31	Sample #31	Sample #39	Sample #39

10. After incubation, discard solutions from the LPA Detection Plate and wash with 200 µL/well of the 1X PBST (step 1) three times. Ensure all wash buffer is removed before proceeding to the next step.
11. Add 100 µL/well of the TMB Substrate (K-TMB1) and incubate for 30 minutes in a dark location. Then add 50 µL 1N Sulfuric Acid (K-STOPT) to each well of the Microtiter Plate to stop the reaction. Read Microtiter Plate absorbance at 450 nm.

Quantification of samples

Generate a best fit curve for the LPA standards in order to interpolate relative sample values. The example LPA standard curve, to the right, shows a 7 point LPA curve that was generated using non-linear regression analysis with Graphpad Software. A semi log [Sigmoidal dose-response (variable slope)] (4 parameter) analysis was utilized. For best results, constrain the standard curve top & bottom using the positive and negative controls. If samples have been diluted, the dilution factor must be multiplied back into the concentration calculated.



Support Protocols for sample preparation

Preparation of Plasma

Materials and Equipment

- Human blood sample.
- Vacutainer tubes containing anticoagulant
- Serological pipettes of appropriate volumes (sterile), centrifuge tubes, cryovials
- Benchtop centrifuge (NOT refrigerated) with swing-out rotor and appropriate carriers

Procedure

1. Draw blood into vacutainer tube(s) containing anticoagulant following local standard operating procedures (this may vary depending on manufacturer). Be sure to draw the full volume to ensure the correct blood-to-anticoagulant ratio.
2. Invert vacutainer tubes carefully 10 times to mix blood and anticoagulant and store at room temperature until centrifugation.
3. Samples should undergo centrifugation immediately. This should be carried out for a minimum of 10 minutes at 1000-2000 RCF (generally 1300 RCF) at room temperature (refer to speeds and times recommended by manufacturer). Do not use brake to stop centrifuge.
4. This will give three layers: (from top to bottom) plasma, leucocytes (buffy coat), erythrocytes. Carefully aspirate the supernatant (plasma) at room temperature and transfer to a centrifuge tube. Take care not to disrupt the cell layer or transfer any cells.
5. Inspect plasma for turbidity. Turbid samples should be centrifuged and aspirated again to remove remaining insoluble matter.
6. Aliquot plasma into cryovials and store at -80°C . Ensure that the cryovials are adequately labeled with the relevant information, including details of additives present in the blood.

Preparation of Serum

Materials and Equipment

- Human blood sample
- Vacutainer tubes (containing either no additive or a clot activator)
- Serological pipettes of appropriate volumes (sterile), centrifuge tubes, cryovials
- Benchtop centrifuge (NOT refrigerated) with swing-out rotor and appropriate carriers

Procedure

1. Draw whole blood into vacutainer tube(s) containing no anticoagulant following local standard operating procedures. Draw approximately $2\frac{1}{2}$ times the volume needed for use e.g. 10 mL blood for 4 mL serum.
2. Incubate in an upright position at room temperature for 30-45 min (no longer than 60 min) to allow clotting. If using a clot-activator tube, invert carefully 5-6 times to mix clot activator and blood before incubation.
3. Centrifuge for 15 minutes at manufacturer's recommended speed (usually 1,000-2,000 RCF). Do not use brake to stop centrifuge.
4. Carefully aspirate the supernatant (serum) at room temperature and transfer into a centrifuge tube, taking care not to disturb the cell layer or transfer any cells. Use a clean pipette for each tube. Inspect the serum for turbidity. Turbid samples should be centrifuged and aspirated again to remove remaining insoluble matter.
5. Aliquot into cryovials and store at -80°C . Ensure that the cryovials are adequately labeled with the relevant information, including details of additives present in the blood.

Preparation of Tissue Homogenate

For tissue homogenate and cell culture samples we recommend $> 30 \mu\text{g}$ of total protein/well. It is highly suggested to determine the amount of total protein/well needed for your sample before you run your experiments. Concentration of the sample may be required.

Procedure

1. Homogenize tissue were tested in the following buffers.
 - a. By sonication in the following homogenization buffer: 20 mM Tris-HCl, pH 7.4; 20% glycerol; 1 mM β -mercaptoethanol; 1 mM EDTA; 1 mM Naorthovanadate; 15 mM NaF; 1 mM PMSF; protease inhibitor cocktail (Sigma); 0.5 mM deoxyypyridoxine; 40 mM β -glycerophosphate. Centrifuge 5 minutes at 5000 x g, 2 - 8°C . The supernatant is then removed and assayed.
 - b. By freeze-defrost cycles in 1X PBS: Rinse tissue in 1X PBS and store overnight in 1X PBS. Perform two freeze-thaw cycles. Centrifuge 5 minutes at 5000 x g, 2 - 8°C . The supernatant is then removed and assayed.
2. Total protein concentration should be measured and the samples diluted with the homogenate buffer to the same protein concentration before being added to the assay.
3. The homogenates can be stored frozen at -80°C until analysis. Avoid repeat freeze-thaw cycles. Centrifuge the sample again after thawing and before added to the assay.

Selected Publications

1. Balood, M., H. Zahednasab, et al. (2014). "Elevated serum levels of lysophosphatidic acid in patients with multiple sclerosis." *Hum Immunol* **75**(5): 411-413.
2. Chattopadhyay, A., M. Navab, et al. (2013). "A Novel Approach to Oral ApoA-I Mimetic Therapy." *J Lipid Res*.
3. Goncalves, I., A. Edsfeldt, et al. (2012). "Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation." *Arterioscler Thromb Vasc Biol* **32**(6): 1505-1512.
4. McArthur, S., T. Gobetti, et al. (2015). "Definition of a Novel Pathway Centered on Lysophosphatidic Acid To Recruit Monocytes during the Resolution Phase of Tissue Inflammation." *J. Immunol*.
5. Simo, K. A., D. J. Niemeyer, et al. (2014). "Altered lysophosphatidic acid (LPA) receptor expression during hepatic regeneration in a mouse model of partial hepatectomy." *HPB (Oxford)* **16**(6): 534-542.
6. Skill, N., J. Wu, et al. (2013). "Lysophosphatidic acid aberrancies and hepatocellular carcinoma: studies in the MDR2 gene knockout mouse." *Cancer Invest* **31**(2): 145-155.

Related Products

Products	Catalog Number
Assays and Enzymes	
Autotaxin Enzyme, active	E-4000
Autotaxin Activity Assay	K-4100
Autotaxin Inhibitor Screening Kits	K-4200, K-4200HTS
Autotaxin ELISA	K-5600
Antibodies	
Anti-LPP3-c-cyto Rabbit Polyclonal Antibody	Z-R018
Anti-LPP3-RGD Rabbit Polyclonal Antibody	Z-R019
Fluorescent ATX Substrates	
FS-3 (lysoPLD)	L-2000
ATAX-red	L-2010

Products	Catalog Number
Lipids	
LPA Biotin	L-012B
LPA C18:1, LPA C18:2, LPA C18:3	L-0181, L-0182, L-0183
Ether-linked LPA	L-0186
LPA C20:0, LPA C20:4	L-0200, L-0204
Inhibitors	
Lipid Phosphate Phosphatase (LPP) inhibitor	L-9218
LPA3 (edg 7) selective ligands	L-9118, L-9318, L-9418, L-9518
BrP-LPA	L-7416
ATX Inhibitors	B-0701, B-0702, L-3223, L-3282, L-7118, L-7218

Please visit our website at www.echelon-inc.com for more lysophospholipid products.



Echelon Biosciences Inc.
675 Arapeen Drive, Suite 302
Salt Lake City, UT 84108
Telephone 866-588-0455
Fax 801-588-0497
echelon@echelon-inc.com
www.echelon-inc.com